Banner - Internal Medicine
Condition and patient type31
In general practice, you see a wide variety of patient types. Regarding these types, the following groups that are at highest risk for IDA include:
- Women with abnormal menstrual cycles, pregnant or breastfeeding, or those who have recently given birth
- Patients who have undergone major surgery or experienced physical trauma
- Patients with gastrointestinal diseases such as Crohn’s disease, celiac disease, or inflammatory bowel disease (IBD)
- Patients with peptic ulcer disease
- Patients who have undergone bariatric procedures such as gastric bypass
- Vegetarians, vegans, and other types whose diets do not include iron-rich foods
Signs and symptoms31
Symptoms of IDA are related to decreased oxygen delivery to the entire body. Your patients with IDA may experience these symptoms:
- Unexplained fatigue
- Dyspnea or chest pain, especially with activity
- Unexplained generalized asthenia
- Rapid heartbeat
- Pounding or "whooshing" in the ears
- Headache, especially with activity
- Pica – an unusual craving for nonfood items
- Hair loss
Diagnosing and managing IDA7,31
IDA is diagnosed through many laboratory tests. Blood tests should include a complete blood count (CBC) and other tests that evaluate iron levels. Different specialties may include additional tests. For example, a gastroenterologist may need to check for blood in the stool to see whether there is internal bleeding.
The more common tests include:
- Hemoglobin and hematocrit
- Serum ferritin
- Transferrin or total iron-binding capacity
Injectafer restores iron
For the treatment of iron deficiency anemia, intravenous (IV) iron should be considered when oral iron is ineffective.
Injectafer is a dextran-free IV iron indicated for adult IDA patients of various etiologies, and only Injectafer provides 1500 mg of iron in just 2 administrations, up to 750 mg each, separated by at least 7 days.
Injectafer has not been studied in pregnant women. Injectafer should be prescribed during pregnancy only if the potential benefit justifies the potential risk to the fetus.
*For adult patients weighing less than 50 kg (110 lb), give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course of treatment.
†When administered via IV infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not <2 mg of iron per mL and administer over at least 15 minutes. When administered as a slow IV push, give at the rate of approximately 100 mg (2 mL) per minute.
Injectafer is not indicated to treat the symptoms of IDA.
Gradient Bar links- Choosing Injectafer
Important Safety Information
Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease.
IMPORTANT SAFETY INFORMATION
Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.
In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.
In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.
In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).
The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports: urticaria, dyspnea, pruritus, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope.
To report adverse events, please contact American Regent at 1-800-734-9236. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.